Current Status and Future Perspectives of Anti-Angiogenic Therapeutic Attempts for Glioblastoma
暂无分享,去创建一个
[1] L. Ricci-Vitiani,et al. Brain Invasion along Perivascular Spaces by Glioma Cells: Relationship with Blood–Brain Barrier , 2019, Cancers.
[2] M. Maurel,et al. Modulation of Gonadotropins Activity by Antibodies , 2019, Front. Endocrinol..
[3] L. Ricci-Vitiani,et al. Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1 , 2018, International journal of cancer.
[4] A. Mercurio,et al. Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and cancer biology , 2018, Science Signaling.
[5] Heiner Koch,et al. The target landscape of clinical kinase drugs , 2017, Science.
[6] Martin Klein,et al. Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.
[7] R. Reis,et al. Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells , 2017, Oncotarget.
[8] D. Ricard,et al. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles , 2017, Journal of extracellular vesicles.
[9] G. Bernardini,et al. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner , 2016, Oncotarget.
[10] Stefano Piccolo,et al. YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.
[11] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[12] Andrew P. Stubbs,et al. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. , 2016, Cancer research.
[13] G. Santoni,et al. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells , 2015, Oncotarget.
[14] R. Bourgon,et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Vernhout,et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.
[16] C. Marosi,et al. Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study , 2014, Anti-cancer drugs.
[17] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[18] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[19] Xing Wu,et al. VEGF Promotes Proliferation of Human Glioblastoma Multiforme Stem-Like Cells through VEGF Receptor 2 , 2013, TheScientificWorldJournal.
[20] P. Kleihues,et al. The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.
[21] M. Shibuya. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. , 2011, Genes & cancer.
[22] M. Gore,et al. Axitinib for the Management of Metastatic Renal Cell Carcinoma , 2011, Drugs in R&D.
[23] C. Porta,et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. , 2011, Anticancer research.
[24] Zena Wilson,et al. Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family , 2011, Molecular Cancer Therapeutics.
[25] Susan M. Chang,et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). , 2010, Neuro-oncology.
[26] S. Hansen,et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. , 2010, Neuro-oncology.
[27] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[28] G. Fuller,et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.
[29] P. Keegan,et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.
[30] Gerhard Christofori,et al. The angiogenic switch in carcinogenesis. , 2009, Seminars in cancer biology.
[31] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[33] R. Jain,et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.
[34] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[35] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] K. Aldape,et al. VEGF Trap induces antiglioma effect at different stages of disease. , 2008, Neuro-oncology.
[37] P. O'Connor,et al. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.
[38] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[39] Kenneth P. Roos,et al. Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.
[40] K. Flaherty,et al. CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[41] Richard Pazdur,et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. , 2007, The oncologist.
[42] Qiulian Wu,et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.
[43] Daniel J Brat,et al. 'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.
[44] Lena Claesson-Welsh,et al. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.
[45] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[46] K. Plate,et al. The Role of Angiopoietins During Angiogenesis in Gliomas , 2005, Brain pathology.
[47] Erwin G. Van Meir,et al. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. , 2005, Neuro-oncology.
[48] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[49] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[50] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[51] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[52] M. Westphal,et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis , 1999, International journal of cancer.
[53] G. Semenza,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[54] Pedro Cuatrecasas,et al. Local aggregation of hormone–receptor complexes is required for activation by epidermal growth factor , 1979, Nature.
[55] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[56] R. Pallini,et al. Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation , 2019, Oncogene.
[57] I. Salmon,et al. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma , 2017, Journal of Neuro-Oncology.
[58] H. Wakimoto,et al. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma , 2014, Journal of Neuro-Oncology.
[59] C. Marosi,et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). , 2014, Neuro-oncology.
[60] P. Keegan,et al. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. , 2010, The oncologist.
[61] A. Bikfalvi,et al. Tumor angiogenesis , 2020, Advances in cancer research.
[62] K. Plate,et al. Vascular morphology and angiogenesis in glial tumors. , 1995, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.